Karolinska Schizophrenia Project

KaSP is a multimodal observational study with the goal of clarifying underlying mechanisms that cause psychotic disorders, such as schizophrenia. Participants with psychotic symptoms are recruited early after first contact with health care, within 4 weeks of starting anti-psychotic medication, and are compared to controls without psychiatric diagnoses on several measures.

NCT Number	NCT06872463
Lead Sponsor	Karolinska Institutet Collaborators: Region Stockholm
Conditions	Schizophrenia and Disorders with Psychotic Features
Enrollment	200 participants
Start Date	2011-01-25
Primary Completion	2027-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-03-12